Get started
Author

Chih-Chao Hsu

ORCID: 0009-0003-4215-4884
Observed ORCID: 0009-0003-4215-4884
OpenAlex ID: A5086532164
Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation
2024 · Matthew E. Stokes, Kerstin Wenzl, et al. · Nature Communications · 21
Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways
2026 · Hsiling Chiu, Junfei Zhao, et al. · Blood · 4
Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma
2025 · Chad C. Bjorklund, Marta Larrayoz, et al. · Blood Neoplasia · 2
EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma
2025 · Ting-Hsiang Huang, Chih-Chao Hsu, et al. · Blood · 2
PDF
Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway
2023 · Danny Jeyaraju, Ann Polonskaia, et al. · Blood · 2
PDF
Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination
2021 · Aarif Ahsan, Ann Polonskaia, et al. · Blood · 2
Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL
2023 · Chih-Chao Hsu, Hsiling Chiu, et al. · Blood · 1
Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
2022 · Matthew E Stokes, Kerstin Wenzl, et al. · Blood · 1
Golcadomide-Mediated Degradation of Aiolos/Ikaros Synergizes with BET Inhibitors through Bidirectional Restructuring of the Directly Regulated Epigenetic Environment in DLBCL
2024 · Chih-Chao Hsu, Junfei Zhao, et al. · Blood
ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment
2019 · Danny V Jeyaraju, Ekta Kumari, et al. · Blood
Large deletions (>10.9 MB) in 17p and bi-allelic TP53 inactivation events in newly-diagnosed multiple myeloma are associated with higher clonal cell fraction and poor prognosis
2019 · Fadi Towfic, Anjan Thakurta, et al. · Clinical Lymphoma Myeloma & Leukemia
Targeting PRMT5 as a Novel Radiosensitization Approach for Primary and Recurrent Prostate Cancer Treatment
2015 · Chang‐Deng Hu, Xuehong Deng, et al.
Abstract 941: Suppression of the androgen receptor function by c-Jun in prostate cancer via a dual mechanism
2012 · Chih-Chao Hsu, Chang-Deng Hu · Cancer Research
Understanding the role of AP-1 in prostate cancer
2012 · Chih-Chao Hsu · Purdue e-Pubs (Purdue University System)
Works count: 14
Citation count: 35
H-index: 2
I10-index: 1
Year
Topic
Type